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Abstract
Introduction: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally 
presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40–80%. 
LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations 
(small-cell lung carcinoma (SCLC)-like), the second with mutations in TP53 and STK11/KEAP1 
(non-small-cell lung carcinoma (NSCLC)-like). Here we evaluated 11 LCNEC patients with only 
a solitary brain metastasis and evaluate phenotype, genotype and follow-up.
Methods: Eleven LCNEC patients with solitary brain metastases were analyzed. Clinical 
characteristics and survival data were retrieved from medical records. Pathological 
analysis included histomorphological analysis, immunohistochemistry (pRB and Ki-67 PI) 
and next-generation sequencing (TP53, RB1, STK11, KEAP1 and MEN1).
Results: All patients had N0 or N1 disease. Median overall survival (OS) was 12 months 
(95% confidence interval (CI) 5.5–18.5 months). Mean Ki-67 PI was 59% (range 15–100%). 
In 6/11 LCNEC Ki-67 PI was ≤40%. OS was longer for Ki-67 ≤40% compared to >40% 
(17 months (95% CI 11–23 months) vs 5 months (95% CI 0.7–9 months), P = 0.007). Two 
patients were still alive at follow-up after 86 and 103 months, both had Ki-67 ≤40%. 8/11 
patients could be subclassified, and both SCLC-like (n = 6) and NSCLC-like (n = 2) subtypes 
were present. No MEN1 mutation was found.
Conclusion: Stage IV LCNEC with a solitary brain metastasis and N0/N1 disease show in the 
majority of cases Ki-67 PI ≤40% and prolonged survival, distinguishing them from general 
LCNEC. This unique subgroup can be both of the SCLC-like and NSCLC-like subtype.
Introduction
Neuroendocrine neoplasms can originate in various 
organ systems and are subdivided in neuroendocrine 
tumors (NET) and neuroendocrine carcinoma (NEC) (1). 
The most common NEC is small-cell lung carcinoma 
(SCLC), followed by pulmonary large cell neuroendocrine 
carcinoma (LCNEC) (2). Although LCNEC is the second 
most frequent NEC, it represents only 1–3% of all types 
of lung cancer (3, 4). Generally, stage IV LCNEC presents 
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with extensive metastatic disease and poor survival rates 
(<10 months), comparable to SCLC (3, 5). Furthermore, 
Ki-67 proliferation index (PI) of LCNEC is approximately 
in the same range as SCLC (40–80%), whereas the PI is 
distinctly lower in well-differentiated neuroendocrine 
tumors such as typical and atypical carcinoid (0–20%) 
(Fig. 1) (6). Based on mutational analysis, LCNEC can 
be separated into two main molecular subtypes: the first 
with mutations in TP53/RB1 (a hallmark of SCLC), the 
other with mutations in TP53/STK11 and/or KEAP1 genes 
and retained pRB protein expression (non-small-cell lung 
carcinoma (NSCLC)-like) (7, 8). In addition, a LCNEC 
subtype with lower Ki-67 PI was identified having a MEN1 
mutation and, more recently, a study showed overlapping 
molecular alterations between atypical carcinoid and 
LCNEC for TP53, RB1 and MEN1 (7, 9).
In contrast to these high grade neuroendocrine 
carcinomas, a subgroup of NSCLC presents with a solitary 
metastasis, limited to the brain. This subgroup comprises 
7% of NSCLC and shows prolonged survival compared to 
NSCLC with extensive metastatic disease (10). According 
to current guidelines, local radical treatment of the 
lesions may be considered in patients with solitary brain 
metastases and a good performance score (11).
In this study, we present a unique subgroup of 11 
stage IV LCNEC patients harboring a synchronous solitary 
brain metastasis as only metastatic site. We hypothesized 
that those tumors had a lower KI-67 PI than general 
LCNEC and that those tumors were of the NSCLC-like 
molecular subtype. Therefore, tumors were evaluated for 
Ki-67 PI, pRB expression and gene mutations.
Methods
We identified 10 stage IV LCNEC patients who underwent 
surgical resection of synchronous solitary brain 
metastases by screening of pathological reports, making 
use of the nationwide network and registry of histo- and 
cytopathology in the Netherlands (PALGA, 2003-2012) 
(12, 13). Furthermore, we identified one additional LCNEC 
patient treated in our own hospital with lobectomy and 
stereotactic radiotherapy targeting his solitary brain 
metastasis (2015). Clinical characteristics and survival 
data were retrieved from medical records.
All histological samples were centrally reviewed to 
confirm LCNEC diagnosis according to the criteria described 
in the World Health Organization (WHO) classification of 
lung tumors, 2015 (14). Immunohistochemistry (IHC) was 
performed with antibodies against Ki-67 (MIB-1) and pRB 
(13A10) as described earlier (13). Ki-67 PI was assessed semi-
quantitatively by an experienced pulmonary pathologist 
(LH) as is done in usual care in our center (15). Targeted 
next-generation sequencing (NGS) for TP53, RB1, STK11 
and KEAP1 was performed on tumor tissue from available 
formalin-fixed paraffin-embedded (FFPE) blocks of the 
primary tumor and/or the brain metastasis (13). In addition 
mutational analysis for MEN1 was performed by NGS (13).
Median overall survival (OS) was evaluated by 
Kaplan–Meier analysis and differences in survival between 
low and high Ki-67 PI (arbitrary threshold ≤40 vs >40%) 
were tested for significance with log-rank test. P < 0.05 was 
considered significant.
The study protocol was approved by the Medical 
Ethical Committee of the Maastricht University Medical 
Centre (METC azM/UM 14-4-043). The study is performed 
according to the Dutch ‘Federa, Human Tissue and Medical 
Research: Code of conduct for responsible use (2011)’ 
regulations not requiring patients’ informed consent.
Results
Eleven LCNEC patients with a synchronous solitary 
brain metastasis were included in the analysis (Table 1). 
Mean age at diagnosis was 59 years (range 34–72), 
Figure 1
Ki-67 proliferation indices (PIs) in the spectrum of 
pulmonary neuroendocrine neoplasms. 
Carcinoids have a Ki-67 PI ≤20%, whereas LCNEC 
and SCLC generally have a Ki-67 PI >40%. The 
group with Ki-67 PI >20% and ≤40% might be 
considered an intermediate NEN group, including 
high-grade NET and/or low-grade LCNEC, not 
specified in current WHO criteria. The majority of 
LCNEC patients with solitary brain metastases 
have a Ki-67 PI in this category. G1, grade 1; 
LCNEC, large cell neuroendocrine carcinoma;  
NET, neuroendocrine tumor; SCLC, small-cell  
lung carcinoma.
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9/11 patients were male. For five patients, smoking history 
was available and mean packyears exceeded 40 years. 
Seven out of 11 patients had N0 disease, the other four 
patients had N1 disease (4/11). Nine out of 11 patients 
were treated with definitive therapy. Seven of those 
patients underwent lobectomy/pneumonectomy and 
surgical resection of the brain metastasis with all resection 
margins histopathologically free of tumor cells (Table 1: 
patients A-E, J and K). Of the other two patients with 
definitive therapy, one underwent metastasectomy and 
stereotactic radiotherapy + chemotherapy for the primary 
tumor (G). The other one underwent a lobectomy and 
stereotactic radiotherapy for his metastasis (F).
Mean Ki-67 PI was 59% (range 15–100%, Table 2). In 
6/11 LCNEC Ki-67 PI was ≤40%. Both tumors with a low 
Ki-67 PI of 15% were diagnosed as LCNEC because of the 
presence of necrosis and a mitotic index of 14 and >30 per 
10 high power fields, respectively (patients F and H). The 
patients had a median OS of 12 months (95% confidence 
Interval (CI) 5.5–18.5 months). A significant prolonged 
OS was seen in patients with a Ki-67 PI ≤40% compared 
to >40% (17 months (95% CI 11.0–23.0 months) vs 
5 months (95% CI 0.7–9.3 months), P = 0.007; Fig. 2). 
Two patients were still alive after 5 years, a remarkable 
longer time than average in stage IV LCNEC patients 
(Tables 1 and 2: patients G and K). A male patient of 58 
years with T2N0 disease who underwent lobectomy and 
metastasectomy (largest tumor part 25 × 20 × 20 mm, Ki-67 
PI 30%), had pulmonary recurrence after 51 months but 
was still alive at follow-up after 103 months. A woman of 
34 years with T1N0 disease underwent a metastasectomy 
(two parts of tumor tissue, cross sections 8 mm and 
22 mm, Ki-67 PI 40%) and was treated with 
chemotherapy and radiotherapy for the primary tumor. 
She was still alive after 86 months of follow-up, without 
recurrence of disease.
Tissue material of all patients was examined with IHC 
and NGS (Table 2 and Supplementary Table 1, see section 
on supplementary data given at the end of this article). 
In seven patients samples from both primary tumors 
and brain lesions were available. Four LCNEC patients 
(A-D) had a RB1 (and TP53) mutation with loss of pRB 
protein expression in IHC analysis, classifying as SCLC-
like subtype. Two LCNEC patients (E and F) had a TP53 
mutation in combination with loss of pRB expression and 
were therefore also regarded as SCLC subtype. Absence of 
RB1 mutation and retained pRB expression was observed 
in two LCNEC patients (G and H), classifying them as 
NSCLC-like subtype. Both NSCLC-like tumors had low 
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a RB1 mutation, but retained pRB expression. Another 
tumor (J) was RB1 wildtype and had a KEAP1 mutation, 
but showed also loss of pRB expression. The last LCNEC (K) 
had KEAP1 and TP53 mutations in the primary tumor (no 
pRB available) and additional STK11 and RB1 mutations as 
well as a different TP53 mutation in the metastatic lesion. 
Therefore, those last three tumors could not definitely be 
classified as SCLC-like or NSCLC-like LCNEC. No MEN1 
mutations were identified in the LCNEC cases.
Discussion
We here present the clinical and molecular features of a 
unique Dutch multicenter cohort of 11 LCNEC patients 
with synchronous solitary brain metastases. Whereas the 
majority of stage IV LCNEC patients endure an aggressive 
disease, this subgroup presents with limited disease 
and a relatively low Ki-67 PI. Stage IV LCNEC thus is a 
heterogeneous disease.
In this series, OS was 12 months and two long-term 
survivors (>5 years) were observed. On the contrary, stage 
IV LCNEC generally presents as disseminated disease with 
limited survival time (3, 5). So far, only few series including 
oligometastatic LCNEC patients have been reported, and 
this is the first series describing solely LCNEC patients 
with solitary brain metastases (16, 17). Furthermore, only 
a minority of patients with stage IV LCNEC present with 
N0/N1 disease. In our recent study, 27% of patients had 
N0/N1 disease (extracted from (13)). Remarkably, in this 
series of patients with solitary metastases, 64% of patients 
have N0 disease and 36% N1 disease.
The prolonged survival of patients in this study with 
a Ki-67 PI ≤40% suggests that Ki-67 PI might be used as 
a prognostic factor in LCNEC patients with solitary brain 
metastases. A prognostic role for Ki-67 PI has already 
been shown in pulmonary neuroendocrine neoplasms, 
specifically separating favorable subgroups with Ki-67 
PI <25 vs ≥25% (18). The current WHO guideline for 
lung cancer does not include Ki-67 PI for classification 
of neuroendocrine neoplasms (14). However, Ki-67 PI 
has been shown to be ≤20% for pulmonary NET and 
>40% for NEC (6). Although the mean value of Ki-67 
PI in this study was 59% and therefore falls within the 
NEC category, the majority of the patients had a Ki-67 PI 
≤40%. This implicates that a subgroup of neuroendocrine 
neoplasms with a Ki-67 PI >20% but ≤40% does exist (Fig. 
1). This subgroup might comprise high-grade NET, which 
has been recently described in several studies although 
not recognized in current WHO classification (19, 20, 
21). However, in those series, the tumors had a carcinoid 
morphology and absence of TP53 and RB1 mutations. In 
contrast, in our study all patients had LCNEC morphology 
and all exhibited TP53 and/or RB1 mutations or loss of 
pRB expression but no MEN1 mutations. Therefore, the 
patients in this study more likely comprise low-grade 
LCNEC with a Ki-67 PI >20 but ≤40% (Fig. 1).
Since the solitary metastatic state is clinically more 
comparable to NSCLC than to SCLC, we hypothesized 
that most LCNEC patients with solitary metastases would 
be of the NSCLC-like subtype. However, six patients 
were classified as SCLC-like and only two as NSCLC-like. 
The remaining three patients could not definitively be 




Ki-67 PI prim Ki-67 PI meta pRB prim pRB meta Primary Metastasis
SCLC-likea
 A 3 N/a 90% neg neg TP53/RB1 TP53/RB1
 B 7 40% 40% neg neg RB1 RB1
 C 12 90% N/a neg neg TP53/RB1 TP53/RB1
 D 18 N/a 30% neg neg TP53/RB1 TP53/RB1
 E 12 90% 80% neg N/a TP53 TP53
 F 17 15% N/a neg N/a TP53 N/a
NSCLC-likea
 G >86 N/a 40% N/a pos N/a TP53/STK11/KEAP1
 H 13 N/a 15% N/a pos N/a TP53
Indefinitea
 I 5 N/a 100% N/a pos N/a TP53/RB1
 J 3 90% 70% neg neg KEAP1 KEAP1
 K >103 N/a 30% N/a neg TP53/KEAP1 TP53 (different)/RB1/KEAP1/STK11
aSCLC-like: RB1 mutation and/or no pRB expression. NSCLC-like: RB1 wildtype and retained pRB expression. Indefinite: no classification could be made on 
basis of immunohistochemistry and mutational results.
Ki-67 PI, Ki-67 proliferation index; meta, metastatic lesion; N/a, not available; neg, negative; OS, overall survival; pos, positive; prim, primary tumor.
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subclassified. Interestingly, mutations were identical in 
six out of seven patients with available samples of both 
primary tumor and metastatic lesion. This suggests that 
mutation of TP53, RB1 and/or STK11/KEAP1 occurs 
prior to tumor cell dissemination in LCNEC (8). In one 
patient, a TP53 and KEAP1 mutation was found in the 
primary and metastatic lesion, whereas another TP53 and 
additional RB1 and STK11 mutations were also found in 
the metastasis. This suggests that primary and metastatic 
lesions of this patient were clonally related and additional 
mutations in the metastasis probably developed later in 
tumorigenesis. Mutational characteristics have not been 
reported before for LCNEC patients with solitary brain 
metastases or oligometastatic disease.
Nine of 11 patients in this series were treated with 
definitive therapy (resection or stereotactic radiotherapy) 
for both primary and metastatic lesions, instead of 
standard treatment for stage IV LCNEC with palliative 
chemotherapy. Retrospective studies in NSCLC with 
solitary brain metastases have shown extended OS in 
patients treated with definitive therapy for primary and 
metastatic tumors (22). No data regarding definitive 
therapy is available for solitary metastases in SCLC and 
LCNEC. However, limited data on this subject is available 
for oligometastatic SCLC and LCNEC, revealing prolonged 
OS after definitive therapy (17, 23). Since retrospective 
datasets are prone to confounding by indication, 
prospective randomized trials are necessary to confirm the 
effect of definitive local treatment.
Conclusion
We present 11 LCNEC patients with a solitary brain 
metastasis and relatively low Ki-67 PI in the majority of the 
patients. Although presence of solitary brain metastases 
resembles NSCLC more than SCLC, presence of a solitary 
metastasis was not restricted to NSCLC-like LCNEC. 
Figure 2
(A) Overall survival of LCNEC patients with solitary 
brain metastases (censored at 36 months).  
(B) Overall survival of LCNEC patients with solitary 
brain metastases, exhibiting a Ki-67 proliferation 
index ≤40% or >40% in the primary tumor and/or 
metastasis (censored at 36 months).
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Our data indicate that stage IV LCNEC is a heterogeneous 
disease, not justifying standard treatment with palliative 
chemotherapy in all patients. Instead, in those patients 
a curative treatment strategy for primary and metastatic 
lesions might be considered to improve OS, especially in 
LCNEC with relatively low Ki-67 PI.
Supplementary data
This is linked to the online version of the paper at https://doi.org/10.1530/
EC-19-0372.
Declaration of interest
B C M H reports grants from Bristol-Myers Squibb, non-financial support 
from Abbvie, outside the submitted work. J L D reports personal fees from 
BMS, personal fees from Pfizer, personal fees from Boehringer-Ingelheim, 
personal fees from Novartis, personal fees from Ipsen, outside the 
submitted work. E J M S reports grants from Bristol-Myers Squibb, Astra 
Zeneca, Pfizer, Novartis and MSD, personal fees from AbbVie and Roche, 
non-financial support from Abbvie, outside the submitted work. A-M C D 
reports grants from Bristol-Myers Squibb, personal fees from Roche, BMS, 
Eli Lily, Takeda and Boehringer Ingelheim, non-financial support from 
Abbvie, outside the submitted work. The other authors have nothing to 
disclose.
Funding
This research did not receive any specific grant from any funding agency in 
the public, commercial or not-for-profit sector.
Statement of ethics
This study is performed in accordance with the World Medical Association 
Declaration of Helsinki and the Dutch ‘Federa, Human Tissue and Medical 
Research: Code of conduct for responsible use (2011)’ regulations not 
requiring patients’ informed consent.
Author contribution statement
E J M Speel and A-M C Dingemans contributed equally to this work.
References
 1 Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, 
Brambilla E, Busam KJ, de Krijger RR, Dietel M, El-Naggar AK, et al. 
A common classification framework for neuroendocrine neoplasms: 
an International Agency for Research on Cancer (IARC) and World 
Health Organization (WHO) expert consensus proposal. Modern 
Pathology 2018 31 1770–1786. (https://doi.org/10.1038/s41379-018-
0110-y)
 2 Korse CM, Taal BG, van Velthuysen ML & Visser O. Incidence and 
survival of neuroendocrine tumours in the Netherlands according 
to histological grade: experience of two decades of cancer registry. 
European Journal of Cancer 2013 49 1975–1983. (https://doi.
org/10.1016/j.ejca.2012.12.022)
 3 Derks JL, Hendriks LE, Buikhuisen WA, Groen HJ, Thunnissen E, 
van Suylen RJ, Houben R, Damhuis RA, Speel EJ & Dingemans AM. 
Clinical features of large cell neuroendocrine carcinoma: a 
population-based overview. European Respiratory Journal 2016 47 
615–624. (https://doi.org/10.1183/13993003.00618-2015)
 4 Takei H, Asamura H, Maeshima A, Suzuki K, Kondo H, Niki T, 
Yamada T, Tsuchiya R & Matsuno Y. Large cell neuroendocrine 
carcinoma of the lung: a clinicopathologic study of eighty-seven 
cases. Journal of Thoracic and Cardiovascular Surgery 2002 124 
285–292. (https://doi.org/10.1067/mtc.2002.122523)
 5 Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, 
Yokose T, Jiang SX, Inoue T, Nakagawa K, et al. Neuroendocrine 
neoplasms of the lung: a prognostic spectrum. Journal of 
Clinical Oncology 2006 24 70–76. (https://doi.org/10.1200/
JCO.2005.04.1202)
 6 Pelosi G, Rindi G, Travis WD & Papotti M. Ki-67 antigen in lung 
neuroendocrine tumors: unraveling a role in clinical practice. Journal 
of Thoracic Oncology 2014 9 273–284. (https://doi.org/10.1097/
JTO.0000000000000092)
 7 Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, 
Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, et al. Next-
generation sequencing of pulmonary large cell neuroendocrine 
carcinoma reveals small cell carcinoma-like and non-small cell 
carcinoma-like subsets. Clinical Cancer Research 2016 22 3618–3629. 
(https://doi.org/10.1158/1078-0432.CCR-15-2946)
 8 George J, Walter V, Peifer M, Alexandrov LB, Seidel D, Leenders F, 
Maas L, Muller C, Dahmen I, Delhomme TM, et al. Integrative 
genomic profiling of large-cell neuroendocrine carcinomas reveals 
distinct subtypes of high-grade neuroendocrine lung tumors. Nature 
Communications 2018 9 1048. (https://doi.org/10.1038/s41467-018-
03099-x)
 9 Simbolo M, Barbi S, Fassan M, Mafficini A, Ali G, Vicentini C, 
Sperandio N, Corbo V, Rusev B, Mastracci L, et al. Gene expression 
profiling of lung atypical carcinoids and large cell neuroendocrine 
carcinomas identifies three transcriptomic subtypes with specific 
genomic alterations. Journal of Thoracic Oncology 2019 14 1651–1661. 
(https://doi.org/10.1016/j.jtho.2019.05.003)
 10 Torok JA, Gu L, Tandberg DJ, Wang X, Harpole Jr DH, Kelsey CR & 
Salama JK. Patterns of distant metastases after surgical management 
of non-small-cell lung cancer. Clinical Lung Cancer 2017 18 e57–e70. 
(https://doi.org/10.1016/j.cllc.2016.06.011)
 11 Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, 
Mok TS, Reck M, Van Schil PE, Hellmann MD, et al. Metastatic 
non-small cell lung cancer: ESMO clinical practice guidelines for 
diagnosis, treatment and follow-up. Annals of Oncology 2018 29 
iv192–iv237. (https://doi.org/10.1093/annonc/mdy275)
 12 Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van 
Krieken JH & Meijer GA. Pathology databanking and biobanking 
in the Netherlands, a central role for PALGA, the nationwide 
histopathology and cytopathology data network and archive. Cellular 
Oncology 2007 29 19–24. (https://doi.org/10.1155/2007/971816)
 13 Derks JL, Leblay N, Thunnissen E, van Suylen RJ, den Bakker M, 
Groen HJM, Smit EF, Damhuis R, van den Broek EC, Charbrier A, 
et al. Molecular subtypes of pulmonary large-cell neuroendocrine 
carcinoma predict chemotherapy treatment outcome. Clinical Cancer 
Research 2018 24 33–42. (https://doi.org/10.1158/1078-0432.CCR-17-
1921)
 14 Travis WD, Brambilla E, Burke AP, Markx A & Nicholson AG. WHO 
Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed. 
Lyon, France: International Agency for Research on Cancer, 2015.
 15 Warth A, Fink L, Fisseler-Eckhoff A, Jonigk D, Keller M, Ott G, 
Rieker RJ, Sinn P, Soder S, Soltermann A, et al. Interobserver 
agreement of proliferation index (Ki-67) outperforms mitotic count 
in pulmonary carcinoids. Virchows Archiv 2013 462 507–513. 
(https://doi.org/10.1007/s00428-013-1408-2)
 16 Kotecha R, Zimmerman A, Murphy ES, Ahmed Z, Ahluwalia MS, 
Suh JH, Reddy CA, Angelov L, Vogelbaum MA, Barnett GH, 
et al. Management of brain metastasis in patients with 
pulmonary neuroendocrine carcinomas. Technology in 
Cancer Research and Treatment 2016 15 566–572. (https://doi.
org/10.1177/1533034615589033)
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-19-0372
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 02/27/2020 10:49:04AM
via University of Groningen and Bibliotheek der Rijksuniversiteit Groningen





 17 Naidoo J, Santos-Zabala ML, Iyriboz T, Woo KM, Sima CS, Fiore JJ, 
Kris MG, Riely GJ, Lito P, Iqbal A, et al. Large cell neuroendocrine 
carcinoma of the lung: clinico-pathologic features, treatment, and 
outcomes. Clinical Lung Cancer 2016 17 e121–e129. (https://doi.
org/10.1016/j.cllc.2016.01.003)
 18 Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, 
Campanini N, Carbognani P, De Pas TM, Galetta D, et al. Grading 
the neuroendocrine tumors of the lung: an evidence-based proposal. 
Endocrine-Related Cancer 2014 21 1–16. (https://doi.org/10.1530/ERC-
13-0246)
 19 Rekhtman N, Desmeules P, Litvak AM, Pietanza MC, Santos-
Zabala ML, Ni A, Montecalvo J, Chang JC, Beras A, Preeshagul IR, 
et al. Stage IV lung carcinoids: spectrum and evolution of 
proliferation rate, focusing on variants with elevated proliferation 
indices. Modern Pathology 2019 32 1106–1122. (https://doi.
org/10.1038/s41379-019-0248-2)
 20 Quinn AM, Chaturvedi A & Nonaka D. High-grade neuroendocrine 
carcinoma of the lung with carcinoid morphology: a study of 
12 cases. American Journal of Surgical Pathology 2017 41 263–270. 
(https://doi.org/10.1097/PAS.0000000000000767)
 21 Vivero M & Scholl LM. ‘Borderline’ neuroendocrine carcinomas 
of the lung are clinically and genomically distinct from large cell 
neuroendocrine carcinoma. Modern Pathology 2016 29.
 22 Li D, Zhu X, Wang H, Qiu M & Li N. Should aggressive thoracic 
therapy be performed in patients with synchronous oligometastatic 
non-small cell lung cancer? A meta-analysis. Journal of Thoracic 
Disease 2017 9 310–317. (https://doi.org/10.21037/jtd.2017.02.21)
 23 Xu LM, Cheng C, Kang M, Luo J, Gong LL, Pang QS, Wang J, 
Yuan ZY, Zhao LJ & Wang P. Thoracic radiotherapy (TRT) improved 
survival in both oligo- and polymetastatic extensive stage small cell 
lung cancer. Scientific Reports 2017 7 9255. (https://doi.org/10.1038/
s41598-017-09775-0)
Received in final form 4 November 2019
Accepted 14 November 2019
Accepted Preprint published online 18 November 2019
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International License.https://doi.org/10.1530/EC-19-0372
https://ec.bioscientifica.com © 2019 The authors
Published by Bioscientifica Ltd
Downloaded from Bioscientifica.com at 02/27/2020 10:49:04AM
via University of Groningen and Bibliotheek der Rijksuniversiteit Groningen
